Peter Ulrich
Overview
Explore the profile of Peter Ulrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kobbe G, Bruggemann M, Baermann B, Wiegand L, Trautmann H, Yousefian S, et al.
N Engl J Med
. 2024 Nov;
391(13):1217-1226.
PMID: 39589371
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary...
2.
Prior H, Andrews L, Cauvin A, Chien H, Clarke D, Datta K, et al.
Regul Toxicol Pharmacol
. 2023 Jan;
138:105339.
PMID: 36649820
Assessment of reversibility from nonclinical toxicity findings in animals with potential adverse clinical impact is required during pharmaceutical development, but there is flexibility around how and when this is performed...
3.
Chien H, Prior H, Andrews L, van Aerts L, Cauvin A, Clarke D, et al.
Regul Toxicol Pharmacol
. 2023 Jan;
138:105329.
PMID: 36592682
To support registration of monoclonal antibodies (mAbs) for chronic indications, 6-month toxicity studies have historically been conducted. Experience with mAb development has shown a relatively benign and well-understood safety profile...
4.
Flandre T, Mansfield K, Espie P, Rubic-Schneider T, Ulrich P
Toxicol Pathol
. 2022 Jun;
50(5):712-724.
PMID: 35730205
CFZ533 (iscalimab) is a nondepleting anti-CD40 antibody intended for inhibition of transplant organ rejection and treatment of autoimmune diseases. In a safety assessment in rhesus monkeys, CFZ533 was administered for...
5.
Hey A, Baumann A, Kronenberg S, Blaich G, Mohl S, Fagg R, et al.
Int J Toxicol
. 2021 Feb;
40(3):270-284.
PMID: 33631988
Safety assessment of biological drugs has its challenges due to the multiple new different modalities, for example, antibody-drug conjugates, bispecifics, nanobodies, fusion proteins and advanced therapy medicinal products (ATMPs), their...
6.
Bolt M, Whiteley L, Lynch J, Lauritzen B, de Henestrosa A, MacLachlan T, et al.
Mol Ther Methods Clin Dev
. 2020 Oct;
19:89-98.
PMID: 33024793
Nonclinical development strategies for gene therapies are unique from other modalities. The European Federation of Pharmaceutical Industries and Associates (EFPIA) Gene Therapy Working Group surveyed EFPIA member and nonmember pharmaceutical...
7.
Chatzikonstantinou G, Ulrich P, Archavlis E, Zamboglou N, Strouthos I, Zoga E, et al.
J Contemp Brachytherapy
. 2019 Aug;
11(3):215-220.
PMID: 31435428
Purpose: To report our results of image-guided interstitial (IRT) high-dose-rate (HDR) brachytherapy (BRT) in the primary treatment of patients with inoperable glioblastoma multiforme (GBM) in the pre-temozolomide period. Material And...
8.
Ulrich P, Flandre T, Espie P, Sickert D, Rubic-Schneider T, Shaw D, et al.
Toxicol Sci
. 2018 Aug;
166(1):192-202.
PMID: 30099540
CFZ533 is a pathway blocking, nondepleting anti-CD40 antibody that is in clinical development for inhibition of transplant organ rejection and therapy for autoimmune diseases. A 26-week GLP toxicity study in...
9.
Ristov J, Espie P, Ulrich P, Sickert D, Flandre T, Dimitrova M, et al.
Am J Transplant
. 2018 Apr;
18(12):2895-2904.
PMID: 29665205
The CD40-CD154 costimulatory pathway is essential for T cell-dependent immune responses, development of humoral memory, and antigen presenting cell function. These immune functions have been implicated in the pathology of...
10.
Ulrich P, Blaich G, Baumann A, Fagg R, Hey A, Kiessling A, et al.
Regul Toxicol Pharmacol
. 2018 Jan;
94:91-100.
PMID: 29355662
Biological drugs comprise a wide field of different modalities with respect to structure, pharmacokinetics and pharmacological function. Considerable non-clinical experience in the development of proteins (e.g. insulin) and antibodies has...